Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon

Arthritis Rheum. 1997 Feb;40(2):352-7. doi: 10.1002/art.1780400220.

Abstract

Objective: To assess the effects of oral L-arginine supplementation on cutaneous vascular responses in patients with primary Raynaud's phenomenon (RP).

Methods: Double-blind, crossover comparison of placebo versus L-arginine (8 gm/day for 28 days). Cutaneous vascular responses in the fingers were assessed during iontophoresis of acetylcholine and sodium nitroprusside, which are endothelium-dependent and endothelium-independent vasodilators.

Results: In comparison with control subjects, patients with primary RP had diminished endothelium-dependent and -independent vasodilatation (P < 0.05, and P < 0.005, respectively, by analysis of variance). At the 3 doses used, vascular responses to acetylcholine were reduced by 71%, 64%, and 63%, respectively, and responses to sodium nitroprusside were reduced by 67%, 73%, and 66%, respectively. L-arginine had no significant effect on cutaneous vascular responses to acetylcholine or sodium nitroprusside in control subjects or patients with primary RP.

Conclusion: Reduced vasodilator ability in primary RP is unlikely to be due to an impairment in the L-arginine/nitric oxide pathway.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Administration, Oral
  • Adult
  • Arginine / administration & dosage*
  • Double-Blind Method
  • Drug Tolerance
  • Erythrocytes / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / blood
  • Nitroprusside / pharmacology
  • Patient Compliance
  • Placebos
  • Raynaud Disease / physiopathology*
  • Skin / blood supply*
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Placebos
  • Vasodilator Agents
  • Nitroprusside
  • Nitric Oxide
  • Arginine
  • Acetylcholine